Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.
first published: Jan 12, 2017 01:07 pm
A collection of the most-viewed Moneycontrol videos.
Groww CEO Lalit Keshre on ₹62,000 Crore IPO, Sebi regulations, valuation expectation and more
How Income Plus Arbitrage Fund of Fund Can Help You Get Stable, Tax-Efficient Returns
Nifty fails to hold 26,000, slips below 25,900 | Closing Bell
Live: Will Nifty bulls take it to new highs after Fed outcome? | Opening Bell
